ONC on Nasdaq
BeOne Medicines Ltd.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with Elanco, Organon & Co. or Catalent Pharma Solutions, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
87.5%Gross margin3
8.4%Operating margin3
5.4%Net margin3
40.2%Revenue growth, 20253
6.6%Return on equity3
0.22×Debt to equity3
$941.7MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Products and services
Product brought in 99% of the revenue BeOne Medicines Ltd. broke down this way in fiscal 2025.
Products and services by year
| Products and services | 2023 | 2024 | 2025 |
|---|---|---|---|
| Product | $2.2B | $3.8B | $5.3B |
| Collaboration | $268.9M | $30.7M | $61.0M |
Regions
United States brought in 54% of the revenue BeOne Medicines Ltd. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $1.1B | $2.0B | $2.9B |
| China | $1.1B | $1.4B | $1.7B |
| Europe | $202.0M | $362.6M | $611.4M |
| All Other Countries Except China, United States Of America, And Switzerland | $26.6M | $78.8M | $171.8M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Research and development40¢$2.1B
- Selling, general and admin39¢$2.1B
- Other costs13¢$698.8M
- Income tax2¢$129.9M
- Profit5¢$286.9M
Out of $5.3B in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Capital spending16¢$185.8M
- Kept or used elsewhere84¢$941.7M
Out of $1.1B of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Total revenues | $5.3B | $3.8B | $2.5B |
| Gross profit | $4.7B | $3.2B | $2.1B |
| Research and development | $2.1B | $2.0B | $1.8B |
| Selling, general and administrative | $2.1B | $1.8B | $1.5B |
| Total operating expenses | $4.2B | $3.8B | $3.3B |
| Income (loss) from operations | $447.1M | -$568.2M | -$1.2B |
| Interest income | $70.5M | $69.6M | $78.4M |
| Interest expense | -$58.2M | -$21.8M | -$4.4M |
| Other (expense) income, net | -$42.6M | -$12.6M | $307.9M |
| Income (loss) before income taxes | $416.9M | -$533.0M | -$825.8M |
| Income tax expense | $129.9M | $111.8M | $55.9M |
| Net income (loss) | $286.9M | -$644.8M | -$881.7M |
| Basic (in dollars per share) | $0.20 | -$0.47 | -$0.65 |
| Diluted (in dollars per share) | $0.19 | -$0.47 | -$0.65 |
| Weighted-average shares outstandingbasic (in shares) | 1.4B shares | 1.4B shares | 1.4B shares |
| Weighted-average shares outstanding diluted (in shares) | 1.5B shares | 1.4B shares | 1.4B shares |
| Basic (in dollars per share) | $3 | -$6 | -$8 |
| Diluted (in dollars per share) | $3 | -$6 | -$8 |
| Weighted-average ADSs outstanding, basic (in shares) | 109.1M shares | 105.3M shares | 104.4M shares |
| Weighted-average ADSs outstanding, diluted (in shares) | 113.4M shares | 105.3M shares | 104.4M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $4.5B | $2.6B | $3.2B |
| Accounts receivable, net | $865.1M | $676.3M | |
| Inventories, net | $608.2M | $495.0M | |
| Prepaid expenses and other current assets | $212.8M | $192.9M | |
| Total current assets | $6.2B | $4.0B | |
| Property, plant and equipment, net | $1.6B | $1.6B | |
| Operating lease right-of-use assets | $148.2M | $139.3M | |
| Intangible assets, net | $62.7M | $51.1M | |
| Other non-current assets | $102.4M | $160.5M | |
| Total non-current assets | $2.0B | $1.9B | |
| Total assets | $8.2B | $5.9B | |
| Accounts payable | $479.0M | $405.0M | |
| Accrued expenses and other payables | $1.1B | $803.7M | |
| Tax payable | $41.6M | $25.9M | |
| Operating lease liabilities, current portion | $20.7M | $17.6M | |
| Research and development cost share liability, current portion | $64.3M | $111.2M | |
| Sale of future royalty liability, current portion | $56.7M | $0 | |
| Short-term debt | $57.3M | $851.5M | |
| Total current liabilities | $1.8B | $2.2B | |
| Long-term debt | $961.9M | $166.5M | |
| Sale of future royalty liability, non-current portion | $850.2M | $0 | |
| Operating lease liabilities, non-current portion | $52.9M | $44.3M | |
| Deferred tax liabilities | $53.2M | $42.0M | |
| Research and development cost share liability, non-current portion | $0 | $54.3M | |
| Other long-term liabilities | $80.2M | $66.7M | |
| Total non-current liabilities | $2.0B | $373.8M | |
| Total liabilities | $3.8B | $2.6B | |
| Ordinary shares, $0.0001 par value per share; 1,540,975,898 and 1,387,367,704 shares issued and 1,441,075,618 and 1,387,367,704 shares outstanding as of December 31, 2025 and 2024, respectively | $144.0K | $138.0K | |
| Additional paid-in capital | $12.8B | $12.1B | |
| Accumulated other comprehensive loss | -$78.2M | -$149.0M | |
| Accumulated deficit | -$8.3B | -$8.6B | |
| Total shareholders equity | $4.4B | $3.3B | $3.5B |
| Total liabilities and shareholders equity | $8.2B | $5.9B | |
| Ordinary shares, par value (in dollars per share) | $0.00 | $0.00 | |
| Ordinary shares, shares issued (in shares) | 1.5B shares | 1.4B shares | |
| Ordinary shares, shares outstanding (in shares) | 1.4B shares | 1.4B shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income (loss) | $286.9M | -$644.8M | -$881.7M |
| Depreciation and amortization expense | $141.7M | $171.8M | $87.7M |
| Share-based compensation expense | $510.9M | $441.6M | $367.6M |
| Acquired in-process research and development | $691.0K | $60.0M | $46.8M |
| Amortization of research and development cost share liability | -$101.1M | -$73.2M | -$55.3M |
| Impairment of equity investments | $75.6M | $6.8M | $7.5M |
| Loss on long-term investments | -$596.0K | -$17.2M | -$8.7M |
| Non-cash interest expense | $14.9M | $0 | $0 |
| Deferred income tax expense | $9.5M | $26.0M | $689.0K |
| Gain on BMS termination settlement | $0 | $0 | -$362.9M |
| Other items, net | -$3.0M | $11.2M | -$6.0M |
| Accounts receivable | -$165.0M | -$329.4M | -$188.3M |
| Inventories | -$93.2M | -$91.5M | -$140.9M |
| Other assets | $37.2M | $45.1M | $12.1M |
| Accounts payable | $79.8M | $121.5M | $21.5M |
| Accrued expenses and other payables | $311.8M | $111.4M | $180.1M |
| Deferred revenue | $1.3M | $633.0K | -$255.6M |
| Other liabilities | $19.0M | -$14.8M | $587.0K |
| Net cash provided by (used in) operating activities | $1.1B | -$140.6M | -$1.2B |
| Purchases of property and equipment | -$185.8M | -$492.7M | -$561.9M |
| Purchase of in-process research and development | -$60.7M | -$31.8M | -$15.0M |
| Purchase of intangible assets | -$20.0M | -$4.7M | -$19.4M |
| Purchase of long-term investments | -$11.8M | -$19.0M | -$14.9M |
| Proceeds from sale or maturity of short-term investments | $3.4M | $2.7M | $673.2M |
| Other investing activities | -$1.2M | -$2.9M | -$2.1M |
| Net cash (used in) provided by investing activities | -$276.2M | -$548.4M | $60.0M |
| Proceeds from sale of future royalties | $911.0M | $0 | $0 |
| Proceeds from long-term loan | $850.6M | $9.1M | $22.5M |
| Repayment of long-term loan | -$35.7M | -$28.0M | -$13.7M |
| Proceeds from short-term loans | $233.7M | $868.3M | $661.5M |
| Repayment of short-term loans | -$1.0B | -$704.2M | -$309.6M |
| Payments of debt issuance costs | -$23.4M | $0 | $0 |
| Payments of withholding taxes from share-based awards | -$24.2M | $0 | $0 |
| Proceeds from option exercises and employee share purchase plan | $196.3M | $45.4M | $55.7M |
| Repayment of sale of future royalties liability | -$4.0M | $0 | $0 |
| Other financing activities | $0 | $3.0M | $0 |
| Net cash provided by financing activities | $1.1B | $193.4M | $416.5M |
| Effect of foreign exchange rate changes, net | $60.0M | -$51.7M | -$8.1M |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $2.0B | -$547.2M | -$689.1M |
| Interest paid | $52.5M | $51.2M | $19.8M |
| Accruals for capital expenditures | $57.3M | $70.3M | $91.8M |
| Purchase of in-process research and development included in accounts payable | $0 | $60.0M | $31.8M |
Former names
- BeiGene, Ltd.Aug 28, 2015 to May 27, 20252
Recent filings
- Oct 2, 20264
- Sep 30, 2026144
- Sep 30, 20264
- Sep 16, 20264
- Sep 16, 2026SCHEDULE 13D/A
- Sep 10, 20264
- Sep 8, 2026144
- Sep 3, 20264
- Sep 1, 2026144
- Aug 27, 20264
- Aug 26, 20268-K
- Aug 25, 2026144
- Aug 25, 2026144
- Aug 13, 20264
- Aug 12, 20264
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10